This is a detailed report about one patient's treatment. A 48-year-old woman with primary Sjögren's syndrome developed a serious kidney complication called secondary membranous nephropathy. This caused her to lose large amounts of protein in her urine. Doctors treated her with a steroid (prednisone) and a medication called rituximab, given by infusion.
After the initial treatment, the amount of protein in her 24-hour urine sample dropped from 8.5 grams to 2.2 grams. She received another rituximab infusion six months later, and her protein loss decreased further to 1.3 grams. The report did not mention any side effects or safety problems from the treatment.
It is very important to understand what this report means. This is the story of just one person. There was no comparison to other treatments or to patients who got no treatment. We do not know the long-term results or if this would work for anyone else. The findings are a starting point for future research, not proof that this is an effective treatment.
Readers should see this as a preliminary medical observation. It suggests rituximab might be a treatment option worth studying in larger, controlled trials for this specific kidney problem linked to Sjögren's. It does not provide evidence for how well or how safely it works for the general population.